Followers | 25 |
Posts | 2529 |
Boards Moderated | 0 |
Alias Born | 12/17/2014 |
Thursday, October 05, 2023 8:43:54 AM
Link:
https://finance.yahoo.com/news/bioadaptives-inc-commences-development-supplement-120000120.html
PluriPain®-PMS is an Advanced Derivative of the Company’s Popular Supplement, PluriPain®
LAS VEGAS, NV, Oct. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, announced today the development of PluriPain®-PMS, an advanced, all natural anti-inflammatory and mood-enhancing Women’s Health formula to combat specific symptoms associated with the menstrual cycle.
The extended anti-inflammatory and mood modifying features of PluriPain-PMS are considered to be more effective than PluriPain®, a popular natural supplement for more common types of pain. The improved effects are due to dose rebalancing and the addition of natural ingredients selected for their intended synergistic features. Early test marketing results are favorable.
Edward Jacobs, M.D., CEO BioAdaptives, Inc., stated, “At the request of our female consumers, BioAdaptives is developing a new, enhanced form of PluriPain, our popular all-natural anti-inflammatory supplement. PluriPain-PMS is designed to help manage the symptoms, especially pain and depressive mood, associated with the menstrual cycle and is based upon the addition of new ingredients derived from Traditional Chinese Medicine and Ayurvedic culture. PluriPain-PMS is the first of several products we are developing to support women’s health. BioAdaptives’ new products will be introduced in Q4 2023.”
The global PMS and menstrual health supplements market size was valued at USD 22.6 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030.
BioAdaptives’ drug-free products are formulated to aid in breathing, pain relief, immune defense, cognition, focus, fatigue reduction, sleep, healing, anti-aging and more.
Recent BDPT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:28 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 10/11/2023 07:59:24 PM
- Form 1-Z - • Edgar (US Regulatory) • 08/24/2023 06:40:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:16:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM